Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
In 2021 it paid to stay private when the chips were down
While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.
How long will the good times roll for medtech?
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Kizoo aims to cure ageing
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
